MedTrace Logo

Liver Transplant European Study Into the Prevention of Fungal Infection

NCT01058174 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2024-11-18

No results posted yet for this study

Summary

Prevention of invasive fungal infection in high risk patients following liver transplant.

Conditions

  • Liver Transplantation
  • Mycoses

Interventions

DRUG

micafungin

intravenous infusion

DRUG

fluconazole

intravenous infusion

DRUG

liposomal amphotericin B

intravenous infusion

DRUG

caspofungin

intravenous infusion

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Europe Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-15
Primary Completion
2012-05-03
Completion
2012-05-03

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Portugal
  • Romania
  • Russia
  • Saudi Arabia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01058174 on ClinicalTrials.gov